Develops drugs for various cancers.
Jul 2026Revenue $2.44B/yrExpenses $1.46B/yr
Reached break-even Feb 2017
Figures by year
When did Exelixis become profitable?
Its revenue passed its expenses in Feb 2017. In the 12 months to Jul 2026, revenue was $2.44B and expenses $1.46B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jan 2026 | $2.32B | $1.45B | $872M |
| Jan 2025 | $2.17B | $1.56B | $605M |
| Dec 2023 | $1.83B | $1.66B | $171M |
| Dec 2022 | $1.61B | $1.41B | $201M |
| Dec 2021 | $1.43B | $1.15B | $287M |
| Jan 2021 | $988M | $877M | $110M |
| Jan 2020 | $968M | $598M | $369M |
| Dec 2018 | $854M | $415M | $439M |
| Dec 2017 | $452M | $287M | $166M |
| Dec 2016 | $191M | $220M | −$28.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.